Physician profile
Montgomery E Thorne
NPI 1588661946
$1,882.22
in general payments reported to CMS, 2019-2025
24 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $32.98 · 2021: $167 · 2022: $403 · 2023: $594 · 2024: $284 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.83 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $485.42 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $368.91 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Myriad Women'S Health, INC. | $219.38 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $150.91 | 2022-2025 | Aptima, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Pfizer INC. | $149.54 | 2022-2024 | |
| Asensus Surgical, INC. | $70.40 | 2019 | |
| Sumitomo Pharma America, INC. | $58.41 | 2024 | Gemtesa, Myfembree |
| Myovant Sciences INC. | $48.24 | 2021-2022 | |
| Avion Pharmaceuticals | $41.38 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.80 | 2022 | |
| Biogen, INC. | $25.14 | 2025 | Zurzuvae |
| Organon LLC | $23.94 | 2024 | |
| Shield Therapeutics INC | $23.68 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $21.05 | 2019 | |
| Coopersurgical, INC. | $20.81 | 2024 | Paragard T 380a |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.34 | 2025 | |
| Amgen INC. | $18.46 | 2019 | |
| Meditrina | $17.29 | 2019 | |
| Covidien LP | $16.24 | 2019 | |
| Evofem Biosciences, INC. | $15.11 | 2021 | |
| Mylan Pharmaceuticals INC. | $14.66 | 2022 | |
| Exeltis, USA INC. | $14.33 | 2025 | Slynd |
| Baxter Healthcare | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Montgomery Thorne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.